Portola Pharmaceuticals ticks up despite missing on its Q2 results

Portola Pharmaceuticals (PTLA +1.4%) moves higher today despite posting a Q2 net loss that came in higher than expectations.

Collaboration revenue totaled $2.6M, earned under the company's agreements with Bristol-Myers Squibb and Pfizer, Bayer Pharma and Jansen Pharmaceuticals, Daiichi Sankyo and Lee's Pharmaceutical.

In Q2, 2012, PTLA earned $66.9M in revenues through its collaboration with Novartis at was terminated July 1, 2012.

Cash and equivalents were $235.2M compared with $137.4M as of December 31, 2012.

Comments (0)
Be the first to comment
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs